Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 9, 2011, Pages 1417-1424

  Takuma, Yoshitaka ^a,b   Nouso, Kazuhiro ^c   Makino, Yasuhiro ^a   Gotoh, Tomoyuki ^b   Toshikuni, Nobuyuki ^b   Morimoto, Youichi ^b   Shimomura, Hiroyuki ^b   Yamamoto, Hiroshi ^b  

^a IWAKUNI NATIONAL HOSPITAL   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cryptogenic cirrhosis; Hepatocellular carcinoma; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; DECARBOXYPROTHROMBIN; PROTHROMBIN;

AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CRYPTOGENIC CIRRHOSIS ASSOCIATED HEPATOCELLULAR CARCINOMA; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MICROWAVE COAGULATION THERAPY; MICROWAVE THERAPY; OBESITY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERCUTANEOUS RADIOFREQUENCY ABLATION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 80052365527     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06775.x     Document Type: Article

References (31)

1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 2008; 14: 4300-8.
2. Kudo M, Arii S, Ikai I etal. The nationwide report registered every 2years by the Liver Cancer Study Group of Japan (in Japanese with English abstract). Kanzo 2007; 48: 117-40.
3. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-54.
4. Ayata G, Gordon FD, Lewis WD etal. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum. Pathol. 2002; 33: 1098-104.
5. Yoshioka Y, Hashimoto E, Yatsuji S etal. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J. Gastroenterol. 2004; 39: 1215-18.
6. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12years: analysis of clinical background. J. Gastroenterol. 2003; 38: 954-61.
7. Giannini EG, Marabotto E, Savarino V etal. for the Italian Liver Cancer (ITALICA) group. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin. Gastroenterol. Hepatol. 2009; 7: 580-5.
8. Tokushige K, Hashimoto E, Yatsuji S etal. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J. Gastroenterol. 2010; 45: 960-7.
9. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J. Gastroenterol. 2010; 16: 1436-41.
10. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334: 693-9.
11. Taura K, Ikai I, Hatano E etal. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery 2007; 142: 685-94.
12. Poon RT. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection? Ann. Surg. Oncol. 2007; 14: 541-7.
13. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J. Gastroenterol. 2006; 12: 828-9.
14. Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2009; 7: 800-6.
15. Nonalcoholic steatohepatitis clinical research network. Hepatology 2003; 37: 244.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Practice guidelines committee, American Association for the Study of Liver Diseases. Hepatology 2005; 42: 1208-36.
17. Makuuchi M, Kosuge T, Takayama T etal. Surgery for small liver cancers. Semin. Surg. Oncol. 1993; 9: 298-304.
18. Bugianesi E, Leone N, Vanni E etal. Expanding the natural history of nonalcoholic steatohepatitis from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 129: 134-40.
19. Ohki T, Tateishi R, Shiina S etal. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 2009; 58: 839-44.
20. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J. Gastroenterol. Hepatol. 2009; 24: 248-54.
21. Hui JM, Kench JG, Chitturi S etal. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-7.
22. Sanyal AJ, Banas C, Sargeant C etal. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-9.
23. Ikeda K, Saitoh S, Koida I etal. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
24. Oka H, Kurioka N, Kim K etal. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12: 680-7.
25. Kubo S, Yamamoto T, Ikebe T etal. Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C. Jpn. J. Cancer Res. 1999; 90: 1076-80.
26. Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S, JPHC Study Group. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur. J. Cancer Prev. 2009; 18: 26-32.
27. Hashizume H, Sato K, Takagi H etal. Primary liver cancers with nonalcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 2007; 19: 827-34.
28. Ratziu V, Bonyhay L, Di Martino V etal. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.
29. Ikeda K, Marusawa H, Osaki Y etal. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann. Intern. Med. 2007; 146: 649-56.
30. Ekstedt M, Franzén LE, Mathiesen UL etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
31. Villanova N, Moscatiello S, Ramilli S etal. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-80.